Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARING-AF: Comparison of Dabigatran, Rivaroxaban, and Apixaban in NVAF
NCT02666157Phase 4Unknown
- Sponsor
- National Cheng Kung University Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dabigatran, rivaroxaban, apixaban in Atrial fibrillation (AFib), sponsored by National Cheng Kung University Hospital. Status: unknown.
02
Drugs
dabigatranrivaroxabanapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02666157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666157.